Summary • Cartesian Therapeutics (RNAC) shares rose 6.9% in pre-market trading, reaching $7.18. • Director Timothy C. Barabe purchased 30,000 shares at $6.86, indicating possible insider confidence. • ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback